TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Multiple Dose, Randomized, Three-Period Crossover Study in Healthy Volunteers to Evaluate the Effect of co-Administration of Amantadine 100 mg BID and Oseltamivir 75 mg BID on the Pharmacokinetic Properties of Amantadine and Oseltamivir.
Brief Summary: This study is designed to assess the safety and pharmacokinetic effects of oseltamivir administration alone or in combination with amantadine in healthy volunteers.


Options:
A: Intervention Type: DRUG; Name: amantadine hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: oseltamivir phosphate; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Pardaprunox | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: pramipexole | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Comparator | Intervention Type: DRUG; Name: Pardaprunox; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: pramipexole; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo Comparator; Assigned to Arm(s): 3
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: pardoprunox | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Pardoprunox | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Pardoprunox | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: pardoprunox; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Pardoprunox; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Pardoprunox; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: health education | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: hand hygiene | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: hand hygiene, Device: face masks | Intervention Type: BEHAVIORAL; Name: hand hygiene; Assigned to Arm(s): 2, 3 | Intervention Type: OTHER; Name: health education; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: face masks; Assigned to Arm(s): 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial Comparing the Effect of GnRH Agonist and Antagonist Ovarian Stimulation Protocols in PCOS Patients
Brief Summary: The purpose of this study is to compare pregnancy rates and the occurrence of OHSS in PCOS patients who were treated with GnRH agonist and GnRH antagonist protocols ovarian stimulation during an IVF cycle. Our hypothesis is that the GnRH antagonist protocol reduces the occurrence and severity of OHSS compared to the GnRH agonist protocol.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Patients receiving short protocol IVF/ICSI-treatment. | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Long protocol | Intervention Type: DRUG; Name: Patients receiving short protocol IVF/ICSI-treatment.; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Long protocol; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: Arvekap 0.1mg (Triptorelin, Ipsen, France); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands); Assigned to Arm(s): N/A
C: Arm Label: Observational Cohort; Type: N/A; Interventions: Drug: ganirelix | Arm Label: Historical Controls; Type: N/A; Interventions: Drug: GnRH agonist | Intervention Type: DRUG; Name: ganirelix; Assigned to Arm(s): Observational Cohort | Intervention Type: DRUG; Name: GnRH agonist; Assigned to Arm(s): Historical Controls
D: Arm Label: Antagonist group; Type: EXPERIMENTAL; Interventions: Other: In vitro fertilization | Arm Label: Agonist group; Type: ACTIVE_COMPARATOR; Interventions: Other: In vitro fertilization | Intervention Type: OTHER; Name: In vitro fertilization; Assigned to Arm(s): Agonist group, Antagonist group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Supplemental Benefit of Angiotensin II Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan (SUPPORT Trial)
Brief Summary: The purpose of this study is to investigate whether an angiotensin II receptor blocker (olmesartan), in addition to conventional treatment, will reduce the mortality and morbidity in hypertensive patients with stable chronic heart failure.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Spironolactone; Type: EXPERIMENTAL; Interventions: Drug: Spironolactone | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): Spironolactone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Olmesartan medoxomil; Type: ACTIVE_COMPARATOR; Interventions: Drug: olmesartan medoxomil | Arm Label: Standard therapy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: olmesartan medoxomil; Assigned to Arm(s): Olmesartan medoxomil
C: Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Combination of Telmisartan and Ramipril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Valsartan; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dressing: Comparison of 3-day and 7-day Catheter Dressing Frequency and Efficacy of Antiseptic Impregnated Dressing in Preventing Catheter-related Infection in ICU
Brief Summary: The purpose of this study is to determine whether a catheter dressing every 7th day is not inferior to a catheter dressing every 3 days and if Chlorhexidine impregnated sponges are effective in preventing catheter-related infections in ICUs.


Options:
A: Arm Label: 3-days dressing frequency/CHX sponge; Type: EXPERIMENTAL; Interventions: Device: Chlorhexidine Sponge (Biopatch TM) | Arm Label: 7-days dressing frequency/CHX sponge; Type: EXPERIMENTAL; Interventions: Device: Chlorhexidine Sponge (Biopatch TM), Behavioral: 7-day catheter dressing frequency | Arm Label: 3-days dressing frequency/No CHX sponge; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 7-days dressing change/No CHX sponge; Type: EXPERIMENTAL; Interventions: Behavioral: 7-day catheter dressing frequency | Intervention Type: DEVICE; Name: Chlorhexidine Sponge (Biopatch TM); Assigned to Arm(s): 3-days dressing frequency/CHX sponge, 7-days dressing frequency/CHX sponge | Intervention Type: BEHAVIORAL; Name: 7-day catheter dressing frequency; Assigned to Arm(s): 7-days dressing change/No CHX sponge, 7-days dressing frequency/CHX sponge
B: Arm Label: PVI paint; Type: ACTIVE_COMPARATOR; Interventions: Procedure: skin disinfection prior catheter insertion | Arm Label: PVI scrub and paint; Type: ACTIVE_COMPARATOR; Interventions: Procedure: skin disinfection prior catheter insertion | Arm Label: Chlorhexidine paint; Type: ACTIVE_COMPARATOR; Interventions: Procedure: skin disinfection prior catheter insertion | Arm Label: chlorhexidine scrub and paint; Type: ACTIVE_COMPARATOR; Interventions: Procedure: skin disinfection prior catheter insertion | Intervention Type: PROCEDURE; Name: skin disinfection prior catheter insertion; Assigned to Arm(s): Chlorhexidine paint, PVI paint, PVI scrub and paint, chlorhexidine scrub and paint
C: Arm Label: Oct/Alc; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.1% Octenidine with 30% 1-propanol and 45% 2-propanol | Arm Label: Alc; Type: ACTIVE_COMPARATOR; Interventions: Drug: 74% Ethanol with 10% 2-propanol | Intervention Type: DRUG; Name: 0.1% Octenidine with 30% 1-propanol and 45% 2-propanol; Assigned to Arm(s): Oct/Alc | Intervention Type: DRUG; Name: 74% Ethanol with 10% 2-propanol; Assigned to Arm(s): Alc
D: Intervention Type: DRUG; Name: Skin disinfection; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparing Behavioral Therapies for Treating Adolescents With Post-Traumatic Stress Disorder Related to Sexual Abuse
Brief Summary: Posttraumatic stress disorder (PTSD) is the most common disorder among childhood sexual abuse survivors and is associated with substantial psychosocial and medical problems, but evidence-based treatment for PTSD in adolescents is lacking. This study aims to examine the efficacy and effectiveness of prolonged exposure therapy for adolescents with client-centered therapy.


Options:
A: Arm Label: Trauma-Focused Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Trauma-Focused Cognitive Behavioral Therapy | Arm Label: Waiting List Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Trauma-Focused Cognitive Behavioral Therapy; Assigned to Arm(s): Trauma-Focused Cognitive Behavioral Therapy
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Risk Reduction through Family Therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Risk Reduction through Family Therapy | Intervention Type: BEHAVIORAL; Name: Risk Reduction through Family Therapy; Assigned to Arm(s): 1, 2
C: Arm Label: IPT arm; Type: EXPERIMENTAL; Interventions: Behavioral: interpersonal psychotherapy for groups | Arm Label: CP arm; Type: EXPERIMENTAL; Interventions: Behavioral: creative play therapy | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: interpersonal psychotherapy for groups; Assigned to Arm(s): IPT arm | Intervention Type: BEHAVIORAL; Name: creative play therapy; Assigned to Arm(s): CP arm
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Prolonged Exposure for Adolescents | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Client Centered Therapy | Intervention Type: BEHAVIORAL; Name: Prolonged Exposure for Adolescents; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Client Centered Therapy; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Left Ventricular Assist Device (Impella LP 2.5) vs. Intraaortic Balloon Counterpulsation (IABP) in Patients With Cardiogenic Shock and Acute Coronary Syndromes
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of a left ventricular assist device in comparison to a standard treatment with an intraaortic balloon pump (IABP) in patients with cardiogenic shock due to left ventricular failure following an acute coronary syndrome (myocardial infarction).


Options:
A: Arm Label: CCPR protocol; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: ECPR protocol; Type: EXPERIMENTAL; Interventions: Procedure: Extracorporeal cardiopulmonary resuscitation (ECPR) | Intervention Type: PROCEDURE; Name: Extracorporeal cardiopulmonary resuscitation (ECPR); Assigned to Arm(s): ECPR protocol
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Intraaortic Balloon Pump | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Device: Left Ventricular Assist Device Impella LP 2.5 | Intervention Type: DEVICE; Name: Left Ventricular Assist Device Impella LP 2.5; Assigned to Arm(s): 2 | Intervention Type: DEVICE; Name: Intraaortic Balloon Pump; Assigned to Arm(s): 1
C: Arm Label: Control arm of study; Type: NO_INTERVENTION; Interventions: Device: Counterpulsation with IAB | Intervention Type: DEVICE; Name: Counterpulsation with IAB; Assigned to Arm(s): Control arm of study
D: Arm Label: adrenaline; Type: EXPERIMENTAL; Interventions: Drug: adrenaline | Intervention Type: DRUG; Name: adrenaline; Assigned to Arm(s): adrenaline

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Left Ventricular Assist Device (Impella LP 2.5) vs. Intraaortic Balloon Counterpulsation (IABP) in Patients With Cardiogenic Shock and Acute Coronary Syndromes
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of a left ventricular assist device in comparison to a standard treatment with an intraaortic balloon pump (IABP) in patients with cardiogenic shock due to left ventricular failure following an acute coronary syndrome (myocardial infarction).


Options:
A: Arm Label: Elective IABP Insertion; Type: EXPERIMENTAL; Interventions: Device: Intra-Aortic Balloon Pump | Arm Label: No Planned IABP Insertion; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Intra-Aortic Balloon Pump; Assigned to Arm(s): Elective IABP Insertion
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Intraaortic Balloon Pump | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Device: Left Ventricular Assist Device Impella LP 2.5 | Intervention Type: DEVICE; Name: Left Ventricular Assist Device Impella LP 2.5; Assigned to Arm(s): 2 | Intervention Type: DEVICE; Name: Intraaortic Balloon Pump; Assigned to Arm(s): 1
C: Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: enoxaparin | Arm Label: Fondaparinux; Type: EXPERIMENTAL; Interventions: Drug: Fondaparinux | Intervention Type: DRUG; Name: Fondaparinux; Assigned to Arm(s): Fondaparinux | Intervention Type: DRUG; Name: enoxaparin; Assigned to Arm(s): Enoxaparin
D: Arm Label: IMPELLA LP 2.5; Type: EXPERIMENTAL; Interventions: Device: IMPLELLA LP 2.5 | Arm Label: IABP Intra-aortic balloon pump; Type: ACTIVE_COMPARATOR; Interventions: Device: IABP Intra-aortic balloon pump | Intervention Type: DEVICE; Name: IMPLELLA LP 2.5; Assigned to Arm(s): IMPELLA LP 2.5 | Intervention Type: DEVICE; Name: IABP Intra-aortic balloon pump; Assigned to Arm(s): IABP Intra-aortic balloon pump

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Development and Evaluation of an "E-Visit" Program for the Management of Acne
Brief Summary: The purpose of this study is to test the efficacy, timeliness, and user satisfaction of an online "E-Visit" application that uses store-and-forward technology for acne patients requiring dermatologic care for their condition. Hypotheses:

1. That an "E-Visit" is an effective alternative to in-person clinic care for patients with mild to severe facial acne.
2. That providers and patients will be satisfied with this model.
3. That mean wait times for new and return visits will be reduced through the "E-Visit" model.
4. That this prototype for care will improve clinic workflow, offer additional patient access, and allow urgent cases to be seen earlier.


Options:
A: N/A
B: Intervention Type: DRUG; Name: imiquimod; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Office visit | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: Evisit | Intervention Type: OTHER; Name: Evisit; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Office visit; Assigned to Arm(s): 1
D: Arm Label: Vismodegib 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Vismodegib 150 mg | Intervention Type: DRUG; Name: Vismodegib 150 mg; Assigned to Arm(s): Vismodegib 150 mg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Antipsychotic Discontinuation in Alzheimer's Disease
Brief Summary: In patients with Alzheimer's disease (AD) who respond to antipsychotic treatment of psychosis and/or agitation/aggression, the relapse risk after discontinuation is not established. AD patients with psychosis and/or agitation/aggression receive 16 weeks of open risperidone treatment (Phase A). Responders are then randomized, double-blind, to one of three arms in Phase B: (1) continuation risperidone for 32 weeks, (2) risperidone for 16 weeks followed by placebo for 16 weeks, (3) placebo for 32 weeks. The primary outcome is time to relapse of psychosis/agitation.


Options:
A: Arm Label: Cholinesterase inhibitor only; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cholinesterase Plus Modafinil; Type: EXPERIMENTAL; Interventions: Drug: Modafinil | Intervention Type: DRUG; Name: Modafinil; Assigned to Arm(s): Cholinesterase Plus Modafinil | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cholinesterase inhibitor only
B: Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): N/A
C: Arm Label: Risperidone-risperidone; Type: OTHER; Interventions: Drug: risperidone | Arm Label: Risperidone-Placebo; Type: OTHER; Interventions: Drug: risperidone | Arm Label: Placebo-Placebo; Type: OTHER; Interventions: Drug: risperidone | Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): Placebo-Placebo, Risperidone-Placebo, Risperidone-risperidone
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Valproate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Valproate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Antipsychotic Discontinuation in Alzheimer's Disease
Brief Summary: In patients with Alzheimer's disease (AD) who respond to antipsychotic treatment of psychosis and/or agitation/aggression, the relapse risk after discontinuation is not established. AD patients with psychosis and/or agitation/aggression receive 16 weeks of open risperidone treatment (Phase A). Responders are then randomized, double-blind, to one of three arms in Phase B: (1) continuation risperidone for 32 weeks, (2) risperidone for 16 weeks followed by placebo for 16 weeks, (3) placebo for 32 weeks. The primary outcome is time to relapse of psychosis/agitation.


Options:
A: Arm Label: Risperidone-risperidone; Type: OTHER; Interventions: Drug: risperidone | Arm Label: Risperidone-Placebo; Type: OTHER; Interventions: Drug: risperidone | Arm Label: Placebo-Placebo; Type: OTHER; Interventions: Drug: risperidone | Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): Placebo-Placebo, Risperidone-Placebo, Risperidone-risperidone
B: Arm Label: Decision support intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Goals of care decision support | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Goals of care decision support; Assigned to Arm(s): Decision support intervention
C: Arm Label: Galantamine; Type: EXPERIMENTAL; Interventions: Drug: Galantamine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Galantamine; Assigned to Arm(s): Galantamine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Specialty Palliative Care; Type: EXPERIMENTAL; Interventions: Behavioral: Specialty Palliative Care | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Specialty Palliative Care; Assigned to Arm(s): Specialty Palliative Care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Antipsychotic Discontinuation in Alzheimer's Disease
Brief Summary: In patients with Alzheimer's disease (AD) who respond to antipsychotic treatment of psychosis and/or agitation/aggression, the relapse risk after discontinuation is not established. AD patients with psychosis and/or agitation/aggression receive 16 weeks of open risperidone treatment (Phase A). Responders are then randomized, double-blind, to one of three arms in Phase B: (1) continuation risperidone for 32 weeks, (2) risperidone for 16 weeks followed by placebo for 16 weeks, (3) placebo for 32 weeks. The primary outcome is time to relapse of psychosis/agitation.


Options:
A: Arm Label: Galantamine; Type: EXPERIMENTAL; Interventions: Drug: Galantamine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Galantamine; Assigned to Arm(s): Galantamine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: galantamine hydrobromide; Assigned to Arm(s): N/A
C: Arm Label: Decision support; Type: EXPERIMENTAL; Interventions: Other: Feeding Options in Dementia Decision Aid | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Feeding Options in Dementia Decision Aid; Assigned to Arm(s): Decision support
D: Arm Label: Risperidone-risperidone; Type: OTHER; Interventions: Drug: risperidone | Arm Label: Risperidone-Placebo; Type: OTHER; Interventions: Drug: risperidone | Arm Label: Placebo-Placebo; Type: OTHER; Interventions: Drug: risperidone | Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): Placebo-Placebo, Risperidone-Placebo, Risperidone-risperidone

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preventing Overweight in USAF Personnel: Minimal Contact Program
Brief Summary: The prevalence of overweight in the United States Air Force (USAF) is about 22%. The objective of this study is to compare the effectiveness of a minimal contact behavioral therapy plus usual care group(MCBT+UC) using a controlled experimental comparison of usual care(UC). Subjects are USAF personnel who are 5lbs below their Maximum Allowable Weight (MAW) and heavier. The primary hypothesis is that: MCBT+UC will have significant weight loss as compared to UC.


Options:
A: Intervention Type: BEHAVIORAL; Name: Behavior change on physical activity and diet; Assigned to Arm(s): N/A
B: Arm Label: E1; Type: EXPERIMENTAL; Interventions: Behavioral: Usual Care | Arm Label: A1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Individualized IC treatment | Intervention Type: BEHAVIORAL; Name: Individualized IC treatment; Assigned to Arm(s): A1 | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): E1
C: Arm Label: Lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: control; Type: EXPERIMENTAL; Interventions: Other: control group | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle intervention | Intervention Type: OTHER; Name: control group; Assigned to Arm(s): control
D: Intervention Type: BEHAVIORAL; Name: Face-to-face maintenance program; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Internet maintenance program; Assigned to Arm(s): N/A

Answer: C